# Evidence Lacking for Mental Health Monitoring Technology
The Lampard Inquiry into mental health services heard testimony this week questioning the scientific foundation behind Oxevision, a technology designed to monitor patient wellbeing in hospital settings.
Oxevision uses artificial intelligence and cameras to track patient behavior, movement, and vital signs without direct contact. The system aims to reduce suicide risk and self-harm among hospitalized mental health patients. However, experts presenting evidence to the inquiry raised concerns about the technology's actual effectiveness.
The core problem centers on research gaps. While Oxevision developers promote the system as a safety tool, independent verification of its accuracy and clinical benefits remains limited. Experts told the inquiry that the company had not published sufficient peer-reviewed studies demonstrating that the technology actually prevents adverse outcomes or improves patient safety.
One significant concern involves privacy and patient autonomy. Mental health patients already face heightened vulnerability during hospitalization. Constant AI monitoring raises questions about consent, dignity, and whether surveillance itself creates psychological harm rather than benefit.
The inquiry also heard that implementation across NHS mental health units proceeded without robust testing. Some hospital staff reported difficulty interpreting the system's alerts, and questions arose about whether staff training adequately prepared workers to act on the technology's outputs.
This situation reflects a broader healthcare challenge: the pressure to adopt innovative solutions outpacing rigorous evidence evaluation. Hospitals understandably seek tools to prevent tragedies. Yet deploying unproven technology risks wasting resources and potentially harming the vulnerable populations the systems claim to protect.
The Lampard Inquiry findings may influence whether the NHS continues funding Oxevision across mental health services. Mental health advocates argue that investment should prioritize staffing, therapeutic services, and evidence-based interventions with proven track records. Technology complements care, they note, but cannot replace human connection and clinical expertise.